Want to see JP:4483 full AI Analyst Report?
Top Page
JMDC Inc.
(4483)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥3,594.00
▼(-23.48% Downside)
Action:Downgraded
Date:08/09/26
The score is driven primarily by solid financial performance (profitable growth with positive recent free cash flow), tempered by balance-sheet and cash-flow volatility risks. Technicals are moderately supportive in the near term but constrained by a weak longer-term trend (below the 200-day average). Valuation is the main drag due to a high P/E and low dividend yield.
Positive Factors
Multi-year revenue expansion
Sustained multi-year revenue expansion and solid profitability imply the company’s products and data services have ongoing demand from life sciences and insurers. This durable top-line growth supports reinvestment, scale benefits, and predictable enterprise sales over a 2–6 month horizon and beyond.
Negative Factors
Rising leverage versus earlier years
An increasing leverage profile reduces financial flexibility and raises refinancing risk if growth slows. Higher debt loads can constrain capital allocation, force tighter cash management, and amplify downside during adverse industry or reimbursement shifts over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue expansion
Sustained multi-year revenue expansion and solid profitability imply the company’s products and data services have ongoing demand from life sciences and insurers. This durable top-line growth supports reinvestment, scale benefits, and predictable enterprise sales over a 2–6 month horizon and beyond.
Read all positive factors
JMDC Inc. (4483) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥224.48B
Dividend Yield0.52%
Average Volume (3M)283.60K
Price to Earnings (P/E)32.8
Beta (1Y)0.71
Revenue Growth18.89%
EPS Growth11.66%
CountryJP
Employees2,444
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)105.92
Shares Outstanding65,446,205
10 Day Avg. Volume398,940
30 Day Avg. Volume283,596
Financial Highlights & Ratios
PEG Ratio2.34
Price to Book (P/B)2.53
Price to Sales (P/S)4.20
P/FCF Ratio26.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,335.56Price Target Upside-7.70% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)114.35
Revenue Forecast (FY)¥60.31B
JMDC Inc. Business Overview & Revenue Model
Company Description
JMDC Inc. (4483) is a Japan-based healthcare data and analytics company that collects, structures, and analyzes medical and health-related data to support healthcare stakeholders. The company’s core offerings center on health/medical big-data plat...
How the Company Makes Money
JMDC makes money primarily by monetizing healthcare data through data-driven services delivered to enterprise customers. Key revenue streams typically include: (1) data platform and analytics services sold to life sciences companies, where JMDC pr...
JMDC Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
66
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.34B | 50.46B | 41.72B | 30.57B | 27.81B | 21.81B |
| Gross Profit | 28.93B | 27.69B | 22.47B | 17.10B | 14.77B | 11.63B |
| EBITDA | 14.18B | 13.81B | 11.43B | 7.57B | 7.98B | 6.51B |
| Net Income | 6.93B | 6.76B | 5.96B | 3.32B | 4.27B | 3.25B |
Balance Sheet | ||||||
| Total Assets | 154.06B | 158.54B | 143.02B | 122.45B | 98.57B | 62.05B |
| Cash, Cash Equivalents and Short-Term Investments | 30.78B | 28.95B | 32.18B | 14.47B | 22.78B | 13.19B |
| Total Debt | 51.03B | 52.05B | 46.89B | 37.83B | 20.40B | 17.80B |
| Total Liabilities | 70.85B | 74.35B | 64.54B | 51.76B | 34.04B | 30.89B |
| Stockholders Equity | 83.06B | 83.68B | 78.02B | 70.59B | 64.54B | 31.17B |
Cash Flow | ||||||
| Free Cash Flow | 8.72B | 8.01B | 12.57B | -910.00M | 3.24B | 3.36B |
| Operating Cash Flow | 9.44B | 8.59B | 14.69B | -17.00M | 4.06B | 3.81B |
| Investing Cash Flow | -6.39B | -10.56B | -3.47B | -24.86B | -22.77B | -8.10B |
| Financing Cash Flow | -7.91B | -1.26B | 6.48B | 16.58B | 28.30B | -2.41B |
JMDC Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.04T | 22.39 | 12.38% | 1.16% | 15.76% | 13.53% | |
73 Outperform | ¥29.83B | 8.71 | ― | 2.58% | 4.90% | 60.31% | |
63 Neutral | ¥224.48B | 32.81 | ― | 0.43% | 18.89% | 11.66% | |
56 Neutral | ¥68.02B | 67.16 | 6.35% | ― | 23.30% | -56.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ¥2.17B | -4.06 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:4483
JMDC Inc.
3,430.00
-864.11
-20.12%
JP:2413
M3
1,538.00
-669.10
-30.32%
JP:4480
Medley
2,078.00
-1,102.00
-34.65%
JP:4438
Welby Inc.
257.00
-65.00
-20.19%
JP:9438
MTI Ltd.
553.00
-330.97
-37.44%
JMDC Inc. Corporate Events
JMDC Lifts Full-Year Earnings Outlook on Strong First-Quarter Growth
Aug 5, 2026
JMDC Inc. reported consolidated revenue of ¥12.605 billion for the three months ended June 30, 2026, a 17.5% year-on-year increase, with operating profit rising 17.5% to ¥1.823 billion. Profit attributable to owners of the parent grew 17...
JMDC Finalizes Terms for New Stock Option Grants to Directors and Employees
Jul 16, 2026
JMDC Inc. has finalized the terms for its 19th, 20th and 21st share subscription rights programs, approving stock options for directors, executive officers and employees of the company and its subsidiaries. The 19th program will allocate 6,540 rig...
JMDC Details Relationship With Omron as Controlling Shareholder and Safeguards for Minority Investors
Jun 25, 2026
JMDC Inc. disclosed its current relationship with parent company Omron Corporation, which holds 54.19% of its voting rights after acquiring 15 million JMDC shares via a tender offer in October 2023. Despite one Omron executive officer serving as a...
JMDC Issues Performance-Linked Stock Options to Drive Data-Driven Healthcare Growth
Jun 25, 2026
JMDC Inc. has approved the issuance of new share subscription rights, effectively stock options, to directors, executive officers and employees of the company and its subsidiaries as part of a strategy to support its data-driven healthcare expansi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.